Inventor · disambiguated record
Shigeo Matsuda
Also filed as: MATSUDA SHIGEO
32 granted patents·20 pending applications·464 citations·filing 2000–2025
97Inventor score
Top patents by PatentIndex Score
52 records- 0198US11679158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jun 20, 2023·7 cites·13 claims
- 0298US11633479B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·24 claims
- 0398US11633480B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·28 claims
- 0498US11612657B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 28, 2023·9 cites·30 claims
- 0598US11590229B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Feb 28, 2023·11 cites·29 claims
- 0698US11382979B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 12, 2022·18 cites·30 claims
- 0798US11246933B1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Feb 15, 2022·30 cites·28 claims
- 0898US10369226B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 6, 2019·25 cites·42 claims
- 0998US9061063B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jun 23, 2015·41 cites·32 claims
- 1098US9012498B2Biodegradable lipids for the delivery of active agentsMANOHARAN MUTHIAH·Filed 2011·Granted Apr 21, 2015·104 cites·41 claims
- 1197US9682922B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 20, 2017·39 cites·18 claims
- 1296US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
- 1396US11071784B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jul 27, 2021·5 cites·1 claims
- 1495US11400158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Aug 2, 2022·1 cites·30 claims
- 1595US8975389B2Nucleic acid chemical modificationsMANOHARAN MUTHIAH·Filed 2010·Granted Mar 10, 2015·31 cites·23 claims
- 1694US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
- 1793US10119136B2RNAi agents modified at the 4′-C positionALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Nov 6, 2018·10 cites·18 claims
- 1892US12364762B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 22, 2025·0 cites·14 claims
- 1992US12350338B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 8, 2025·0 cites·14 claims
- 2092US12343398B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jul 1, 2025·0 cites·30 claims
- 2192US12239709B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Mar 4, 2025·0 cites·28 claims
- 2292US8962580B2Chemical modifications of monomers and oligonucleotides with cycloadditionMANOHARAN MUTHIAH·Filed 2009·Granted Feb 24, 2015·26 cites·11 claims
- 2391US6593088B1Reversible photocoupling nucleic acid and phosphoroamiditeJAPAN SCIENCE & TECH CORP·Filed 2000·Granted Jul 15, 2003·45 cites·4 claims
- 2491US2024398956A1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2588US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
- 2688US9453043B2Nucleic acid chemical modificationsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Sep 27, 2016·4 cites·22 claims
- 2788US2023256098A1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2885US11597932B2Chirally-enriched double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·3 cites·24 claims
- 2985US10808246B2Oligonucleotide-ligand conjugates and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Oct 20, 2020·6 cites·9 claims
- 3085US2025207131A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3183US2025043279A1SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3282US2025075208A1Oligonucleotide-ligand conjugates and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3379US12275938B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 15, 2025·0 cites·38 claims
- 3476US2023256001A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3576US2025163417A1Compositions and methods for improving strand biasedALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3672US12247203B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 11, 2025·0 cites·20 claims
- 3772US12173288B2Oligonucleotide-ligand conjugates and process for their preparationALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Dec 24, 2024·0 cites·6 claims
- 3870US2023122244A1Chirally-enriched double-stranded rna agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3969US2025205272A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4065US12173287B2Compositions and methods for improving strand biasedALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Dec 24, 2024·0 cites·20 claims
- 4161US2025075217A1Peptide ligands for cns and ocular delivery of rnai compoundsALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4260US2024409927A1Integrin targeting ligands for ocular delivery of rnai compoundsALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4360US2025223588A1Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4459US2024336914A12'-modified nucleoside based oligonucleotide prodrugsALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4558US2015203847A1Chemical modifications of monomers and oligonucleotides with cycloadditionALNYLAM PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4658US2025270562A1Bis-rnai compounds for cns deliveryALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4757US2016348110A1Nucleic acid chemical modificationsALNYLAM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4856US2019048344A1Chemical modifications of monomers and oligonucleotides with cycloadditionALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4955US10266484B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Apr 23, 2019·0 cites·21 claims
- 5052US2023016929A1Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Shigeo Matsuda files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →